
CERO
Healthcare · Biotechnology · $358,154 market cap
$0.0038-0.00 (-7.3%)Nov 13, 9:30 AM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 19, 2025 | After the close | -4.35 | -9.10 | -109.2% |
| Aug 22, 2025 | After the close | -6.21 | -61.71 | -893.7% |
| May 15, 2025 | After the close | -119.20 | -31.80 | +73.3% |
| Feb 26, 2025 | Time not confirmed | — | -17.49 | — |
| Mar 24, 2023 | Time not confirmed | — | -0.01 | — |
| Nov 10, 2022 | Time not confirmed | — | 7.35 | — |
| Aug 11, 2022 | Time not confirmed | — | -9.71 | — |
| May 13, 2022 | Time not confirmed | — | -0.02 | — |
| Mar 24, 2022 | Time not confirmed | — | -0.01 | — |
| Nov 19, 2021 | Time not confirmed | — | -0.01 | — |
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.